Yaohai is a product supplier that provide essential nutrients for human life. A unique medicine they make are bi-specific VHHs. So what are bi-specific VHH? Those are built from little pieces of the anatomy called antibodies. Antibodies are the little soldiers that our immune system uses to attack illnesses and keep us healthy. VHHs of the bi-specific variety are noteworthy in that they can bind two separate entities at once. They are very useful for the treatment of certain diseases such as some types of cancer.
These bi-specific VHHs are created by Yaohai using unique cells known as “expression hosts, similar to the Yaohai's product like 組み換えインスリンの製造. zia These expression hosts which are trained to produce the very same antibodies that Yaohai wants for her drugs. bi-specific VHHs are difficult to make in practice, though. Sometimes, the cells make antibodies that are NOT formed properly or do not have as well of a response. This is why Yaohai is working day and night to find safer and efficient ways of making bi-specific VHHs.
A bioreactor, shown here, is one way that researchers cultivate stem cells. Bioreactor is great, and it can make many bi-specific VHHs in one go. What that means is instead of being limited to a handful at a time, these VHHs can now be assembled into bi-specifics in spades yielded virtually unlimited supplies of bi-bi-specific VHH. This is not only time-saving, but also facilitates Yaohai to start testing new medicine as soon as possible.
Immunotherapy provides another attractive designation for bi-specific VHHs, just like the レンチウイルスプラスミド製造 produced by Yaohai. Immuno therapeutics are medications that help your body fight off disease — bi-specifically for more severe conditions, like cancer. For example, bi-specific VHHs can bind to cancer cells and the immune system cell to aid the immune system in identifying and eliminating these dangerous cells—useful during with immunotherapy.
Bi-specific VHHs as immuno-therapeutic agents, however, are not trivial to produce, also the Yaohai's product such as GMP 抗 HER3 VHH 製造抗体を作る細胞が疲れて、十分な分子を作れなくなることがあります。あるいは、抗体がヤオハイの期待通りに癌細胞にロックすることができません。これが、ヤオハイがこれらの問題を解決する新しい先進的な方法を探し続け、癌に苦しむ人々のために優れた薬を更新している理由です。
これは患者の血液を採取して検査し、体に役立つ完璧な抗体と、 GMP 抗MMRCD206 VHH manufactured by Yaohai. So, they engineer a bi-specific VHH made up of these specialized antibodies — specifically tailored for that individual. It allows for a personalized touch which means that we can better guarantee that the medicine will work for that particular person.
They have one more fewie, which is called "affinity maturation." This technique makes the bi-specific VHHs adhere to the cancer cells even more efficiently, same with Yaohai's VLPベースのワクチン製造. They are also leveraging several new concepts that can make the bbi-specificVHHs last longer in the body so they do not get cleared away by the immune system. This matters since the longer these antibodies are able to be active (by definition), the more powerful they will be at preventing disease.
Yaohai Bio-Pharma has experience in the manufacture of biologics derived from microorganisms. We offer tailored RD solutions and manufacturing while minimizing the risk. We have worked with diverse methods, such as Bispecific VHH Production of vaccines (including peptides), growth factors, hormones, and Cytokines. We specialized in multiple microbial hosts, including yeast extracellular and intracellular (yield up to 15 g/L) bacteria periplasmic secretion, soluble intracellular, and inclusion bodies (yield up to 10 grams/L). We also have a BSL-2 fermentation platform to create bacterial vaccines. We specialize in improving processes, increasing product yields, as well as reducing production costs. We have an efficient technology team that guarantees timely and quality project delivery. This allows us to deliver your exclusive products quicker to market.
Yaohai BioPharma is a Top 10 Microbial CDMO that incorporates quality control and regulatory matters. We have a quality system which is in line with current GMP standards and international regulations. Our regulatory team is knowledgeable in global regulatory frameworks to accelerate biological launches. We ensure traceable manufacturing processes and top-quality products that are compliant with the requirements of the US FDA, EU EMA, Australia TGA, and Bispecific VHH Production. Yaohai BioPharma has successfully passed the audit on site of the European Union's qualified Person (QP) for our GMP quality system and production site. In addition, we've cleared the first certification audits of the ISO9001 Quality Management System, ISO14001 Environmental Management System, and ISO45001 Occupational Health and Safety Management System.
Bispecific VHH Production is a leading in microbial biologics CDMO. Our focus has been on microbial-produced vaccines and therapeutics that are suited for human, veterinary, as well as pet health management. We have the most cutting-edge RD platforms and manufacturing technology which cover the entire procedure beginning with the development of microbial strains and cell banking, to process and method development, to commercial and clinical production which ensures successful delivery of innovative solutions. Over time, we have accumulated vast knowledge of microbial-based bio processing. Over 200 projects have been successfully completed, and we assist our clients to comply with regulations like those of US FDA and EU EMA. We also help them to navigate Australia TGA and China NMPA. Our professional expertise and extensive experience allows us to quickly respond to market demands and provide bespoke CDMO services.
Yaohai Bio-Pharma, a top 10 producer of biological products, is a specialist in microbial fermentation. We have built an advanced facility that is equipped with advanced facilities as well as robust RD and manufacturing capabilities. Five drug substance production lines that are compliant with GMP standards for microbial purification and fermentation along with two automated fill and finishing lines for vials, cartridges and needles pre-filled are available. The scales for fermentation available are 100L, 500L, 1000L and 2000L. The filling volume ranges from 1ml to Bispecific VHH Production. Syringes or cartridges pre-filled are filled with the equivalent of 1-3ml. Our cGMP-compliant production workshop ensures steady supply of clinical samples and commercial products. The bulk molecules produced in our factory can be shipped worldwide.
Yaohai Bio-Pharma は、14 年以上微生物 CRDMO ソリューションに焦点を当ててきました。当社は世界中のお客様にワンストップの生物製剤サービスを提供しています。
No. 801, Jiankang Avenue, Taizhou, Jiangsu, China
著作権 © Yaohai Biopharmaceutical Co., Ltd. 全著作権所有 | プライバシーポリシー
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
